Congenital Hyperinsulinism Pipeline Insight, 2019
Congenital Hyperinsulinism (CHI) (Neonatal Hyperinsulinism)
Congenital Hyperinsulinism (CHI) - Pipeline Insight, 2019 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Congenital Hyperinsulinism pipeline landscape is provided which includes the disease overview and Congenital Hyperinsulinism treatment guidelines. The assessment part of the report embraces, in depth Congenital Hyperinsulinism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Congenital Hyperinsulinism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Congenital Hyperinsulinism (CHI) Understanding
Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma. Congenital hyperinsulinism affects approximately 1 in 50,000 newborns. This condition is more common in certain populations, affecting up to 1 in 2,500 newborns. Congenital hyperinsulinism, refers to a clinically, genetically and morphologically heterogeneous group of disorders associated with dysregulated insulin secretion. The remarkable progress has been made in the diagnosis and management of CHI, which has directly translated into improved neurological outcomes for patients. This improvement in the understanding of the pathogenesis of CHI and the development of diagnostic modalities have helped in deciding the optimal management strategy for each patient.
Congenital Hyperinsulinism (CHI) Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Congenital Hyperinsulinism targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Congenital Hyperinsulinism pipeline report covers 5+ companies. Some of the key players include Zealand Pharma (Dasiglucagon), Rezolute (RZ358) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Congenital Hyperinsulinism (CHI) Analytical Perspective by DelveInsight
• In-depth Congenital Hyperinsulinism Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Congenital Hyperinsulinism Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Congenital Hyperinsulinism report provides an overview of therapeutic pipeline activity for Congenital Hyperinsulinism across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Congenital Hyperinsulinism therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Congenital Hyperinsulinism Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Congenital Hyperinsulinism
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Congenital Hyperinsulinism to formulate effective R&D strategies
• Assess challenges and opportunities that influence Congenital Hyperinsulinism R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Congenital Hyperinsulinism in licensing and out licensing strategies by identifying prospective partners with progressing projects for Congenital Hyperinsulinism to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugsPlease Note: The report will be delivered in 2-3 business days upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook